ID

31508

Description

Escitalopram in the Treatment of Postpartum Depression; ODM derived from: https://clinicaltrials.gov/show/NCT01527474

Lien

https://clinicaltrials.gov/show/NCT01527474

Mots-clés

Versions (1)
  1. 30/08/2018 30/08/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

30 août 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Postpartum Depression NCT01527474

Anglais

Eligibility Postpartum Depression NCT01527474

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
female between the ages of 19 to 40 years of age
Description

Gender | Age

Type de données

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
given birth in the last 6 months
Description

Birth Recently

Type de données

boolean

Alias
UMLS CUI [1,1]
C0005615
UMLS CUI [1,2]
C0332185
not currently breastfeeding
Description

Breast Feeding Absent

Type de données

boolean

Alias
UMLS CUI [1,1]
C0006147
UMLS CUI [1,2]
C0332197
meet criteria for major depressive disorder as per the diagnostic and statistical manual of mental disorders, 4th edition (dsm-iv tr)
Description

Major Depressive Disorder

Type de données

boolean

Alias
UMLS CUI [1]
C1269683
montgomery-asberg depression rating scale (madrs) score greater than or equal to 25 at enrolment
Description

Montgomery-Asberg Depression Rating Scale Questionnaire

Type de données

boolean

Alias
UMLS CUI [1]
C4054475
able to read and write english
Description

Able to read English Language | Able to write English Language

Type de données

boolean

Alias
UMLS CUI [1,1]
C0586740
UMLS CUI [1,2]
C0376245
UMLS CUI [2,1]
C0584993
UMLS CUI [2,2]
C0376245
sign written informed consent to participate in the study.
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
have a significant risk of suicide according to the investigator's opinion or presents a score of 5 or greater on item 10 (suicidal thoughts) of of the madrs
Description

At risk for suicide | Feeling suicidal MADRS

Type de données

boolean

Alias
UMLS CUI [1]
C0563664
UMLS CUI [2,1]
C0424000
UMLS CUI [2,2]
C4054475
meets dsm-iv-tr criteria for past or current manic or hypomanic episode, past or current psychotic symptoms or disorder, and/or has a history of drug or alcohol abuse/dependence within the last 6 months
Description

Manic episode | Hypomanic episode | Psychotic symptom | Psychotic Disorders | Substance Use Disorders | Substance Dependence

Type de données

boolean

Alias
UMLS CUI [1]
C0349208
UMLS CUI [2]
C1396834
UMLS CUI [3]
C0871189
UMLS CUI [4]
C0033975
UMLS CUI [5]
C0038586
UMLS CUI [6]
C0038580
uses the following disallowed recent or concomitant medication within the specified time periods - any antidepressant or any drug used for augmentation of antidepressant action within the last 2 weeks (5 weeks for fluoxetine) prior to baseline, any benzodiazepines or other anxiolytics within the last week prior to baseline, any non-benzodiazepine hypnotics within the last week prior to baseline, oral antipsychotics within 2 weeks or depot antipsychotics within 6 months prior to baseline, serotonergic medicinal products (for example triptans, tryptophan, tramadol) within the last week prior to baseline, psychoactive herbal remedies (for example st. johns wort, kava kava, valerian, gingko biloba) within the last 2 weeks prior to baseline, any other drug with potential psychotropic effects within the last 2 weeks prior to baseline, any anticonvulsant drug within the last 2 weeks prior to baseline, or any investigational product within 3 months prior to baseline
Description

Antidepressive Agents | Fluoxetine | Benzodiazepines | Anti-Anxiety Agents | Sedative hypnotics (non-benzodiazepines) | Antipsychotic Agents Oral | Antipsychotic Agents Depot | Serotonin Agents | Triptans | Tryptophan | Tramadol | Herbal medicine Psychoactive | ST. JOHN'S WORT EXTRACT | Kava preparation | Valerian | Ginkgo biloba extract | Psychotropic Drugs | Anticonvulsants | Investigational New Drugs

Type de données

boolean

Alias
UMLS CUI [1]
C0003289
UMLS CUI [2]
C0016365
UMLS CUI [3]
C0005064
UMLS CUI [4]
C0040616
UMLS CUI [5]
C3854290
UMLS CUI [6,1]
C0040615
UMLS CUI [6,2]
C1527415
UMLS CUI [7,1]
C0040615
UMLS CUI [7,2]
C0086129
UMLS CUI [8]
C0242701
UMLS CUI [9]
C1567966
UMLS CUI [10]
C0041249
UMLS CUI [11]
C0040610
UMLS CUI [12,1]
C2240391
UMLS CUI [12,2]
C0682880
UMLS CUI [13]
C0813171
UMLS CUI [14]
C0939882
UMLS CUI [15]
C0795674
UMLS CUI [16]
C0772125
UMLS CUI [17]
C0033978
UMLS CUI [18]
C0003286
UMLS CUI [19]
C0013230
is currently receiving formal cognitive or behavioural therapy, systematic psychotherapy, or plans to initiate such therapy during the study
Description

Cognitive Therapy | Behavior Therapy | Psychotherapy systematic | Cognitive Therapy Planned | Behavior Therapy Planned | Psychotherapy systematic Planned

Type de données

boolean

Alias
UMLS CUI [1]
C0009244
UMLS CUI [2]
C0004933
UMLS CUI [3,1]
C0033968
UMLS CUI [3,2]
C0220922
UMLS CUI [4,1]
C0009244
UMLS CUI [4,2]
C1301732
UMLS CUI [5,1]
C0004933
UMLS CUI [5,2]
C1301732
UMLS CUI [6,1]
C0033968
UMLS CUI [6,2]
C0220922
UMLS CUI [6,3]
C1301732
current depressive symptoms of the patient are considered by the investigator to have been resistant to two well-conducted antidepressant treatments of at least 6 weeks duration
Description

Depressive Symptoms | Resistant to Antidepressant therapy Quantity

Type de données

boolean

Alias
UMLS CUI [1]
C0086132
UMLS CUI [2,1]
C0332325
UMLS CUI [2,2]
C1096649
UMLS CUI [2,3]
C1265611
has a serious illness or serious sequelae thereof, including liver or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological (including epilepsy), infectious, neoplastic, or metabolic disturbance (if there is a history of such disease but the condition has been stable for at least one year and is judged by the investigator not to render inclusion unsafe and not to interfere with the patient's participation in the study, the patient may be included.)
Description

Illness Serious | Illness Sequelae Serious | Hepatic Insufficiency | Renal Insufficiency | Cardiovascular Disease | Lung disease | Gastrointestinal Disease | Endocrine System Disease | Nervous system disorder | Epilepsy | Communicable Disease | Neoplastic disease | Metabolic Disease

Type de données

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0205404
UMLS CUI [2,1]
C0221423
UMLS CUI [2,2]
C0243088
UMLS CUI [2,3]
C0205404
UMLS CUI [3]
C1306571
UMLS CUI [4]
C1565489
UMLS CUI [5]
C0007222
UMLS CUI [6]
C0024115
UMLS CUI [7]
C0017178
UMLS CUI [8]
C0014130
UMLS CUI [9]
C0027765
UMLS CUI [10]
C0014544
UMLS CUI [11]
C0009450
UMLS CUI [12]
C1882062
UMLS CUI [13]
C0025517
Retour au début de la page

Similar models

Eligibility Postpartum Depression NCT01527474

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Gender | Age
Item
female between the ages of 19 to 40 years of age
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Birth Recently
Item
given birth in the last 6 months
boolean
C0005615 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
Breast Feeding Absent
Item
not currently breastfeeding
boolean
C0006147 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Major Depressive Disorder
Item
meet criteria for major depressive disorder as per the diagnostic and statistical manual of mental disorders, 4th edition (dsm-iv tr)
boolean
C1269683 (UMLS CUI [1])
Montgomery-Asberg Depression Rating Scale Questionnaire
Item
montgomery-asberg depression rating scale (madrs) score greater than or equal to 25 at enrolment
boolean
C4054475 (UMLS CUI [1])
Able to read English Language | Able to write English Language
Item
able to read and write english
boolean
C0586740 (UMLS CUI [1,1])
C0376245 (UMLS CUI [1,2])
C0584993 (UMLS CUI [2,1])
C0376245 (UMLS CUI [2,2])
Informed Consent
Item
sign written informed consent to participate in the study.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
At risk for suicide | Feeling suicidal MADRS
Item
have a significant risk of suicide according to the investigator's opinion or presents a score of 5 or greater on item 10 (suicidal thoughts) of of the madrs
boolean
C0563664 (UMLS CUI [1])
C0424000 (UMLS CUI [2,1])
C4054475 (UMLS CUI [2,2])
Manic episode | Hypomanic episode | Psychotic symptom | Psychotic Disorders | Substance Use Disorders | Substance Dependence
Item
meets dsm-iv-tr criteria for past or current manic or hypomanic episode, past or current psychotic symptoms or disorder, and/or has a history of drug or alcohol abuse/dependence within the last 6 months
boolean
C0349208 (UMLS CUI [1])
C1396834 (UMLS CUI [2])
C0871189 (UMLS CUI [3])
C0033975 (UMLS CUI [4])
C0038586 (UMLS CUI [5])
C0038580 (UMLS CUI [6])
Antidepressive Agents | Fluoxetine | Benzodiazepines | Anti-Anxiety Agents | Sedative hypnotics (non-benzodiazepines) | Antipsychotic Agents Oral | Antipsychotic Agents Depot | Serotonin Agents | Triptans | Tryptophan | Tramadol | Herbal medicine Psychoactive | ST. JOHN'S WORT EXTRACT | Kava preparation | Valerian | Ginkgo biloba extract | Psychotropic Drugs | Anticonvulsants | Investigational New Drugs
Item
uses the following disallowed recent or concomitant medication within the specified time periods - any antidepressant or any drug used for augmentation of antidepressant action within the last 2 weeks (5 weeks for fluoxetine) prior to baseline, any benzodiazepines or other anxiolytics within the last week prior to baseline, any non-benzodiazepine hypnotics within the last week prior to baseline, oral antipsychotics within 2 weeks or depot antipsychotics within 6 months prior to baseline, serotonergic medicinal products (for example triptans, tryptophan, tramadol) within the last week prior to baseline, psychoactive herbal remedies (for example st. johns wort, kava kava, valerian, gingko biloba) within the last 2 weeks prior to baseline, any other drug with potential psychotropic effects within the last 2 weeks prior to baseline, any anticonvulsant drug within the last 2 weeks prior to baseline, or any investigational product within 3 months prior to baseline
boolean
C0003289 (UMLS CUI [1])
C0016365 (UMLS CUI [2])
C0005064 (UMLS CUI [3])
C0040616 (UMLS CUI [4])
C3854290 (UMLS CUI [5])
C0040615 (UMLS CUI [6,1])
C1527415 (UMLS CUI [6,2])
C0040615 (UMLS CUI [7,1])
C0086129 (UMLS CUI [7,2])
C0242701 (UMLS CUI [8])
C1567966 (UMLS CUI [9])
C0041249 (UMLS CUI [10])
C0040610 (UMLS CUI [11])
C2240391 (UMLS CUI [12,1])
C0682880 (UMLS CUI [12,2])
C0813171 (UMLS CUI [13])
C0939882 (UMLS CUI [14])
C0795674 (UMLS CUI [15])
C0772125 (UMLS CUI [16])
C0033978 (UMLS CUI [17])
C0003286 (UMLS CUI [18])
C0013230 (UMLS CUI [19])
Cognitive Therapy | Behavior Therapy | Psychotherapy systematic | Cognitive Therapy Planned | Behavior Therapy Planned | Psychotherapy systematic Planned
Item
is currently receiving formal cognitive or behavioural therapy, systematic psychotherapy, or plans to initiate such therapy during the study
boolean
C0009244 (UMLS CUI [1])
C0004933 (UMLS CUI [2])
C0033968 (UMLS CUI [3,1])
C0220922 (UMLS CUI [3,2])
C0009244 (UMLS CUI [4,1])
C1301732 (UMLS CUI [4,2])
C0004933 (UMLS CUI [5,1])
C1301732 (UMLS CUI [5,2])
C0033968 (UMLS CUI [6,1])
C0220922 (UMLS CUI [6,2])
C1301732 (UMLS CUI [6,3])
Depressive Symptoms | Resistant to Antidepressant therapy Quantity
Item
current depressive symptoms of the patient are considered by the investigator to have been resistant to two well-conducted antidepressant treatments of at least 6 weeks duration
boolean
C0086132 (UMLS CUI [1])
C0332325 (UMLS CUI [2,1])
C1096649 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Illness Serious | Illness Sequelae Serious | Hepatic Insufficiency | Renal Insufficiency | Cardiovascular Disease | Lung disease | Gastrointestinal Disease | Endocrine System Disease | Nervous system disorder | Epilepsy | Communicable Disease | Neoplastic disease | Metabolic Disease
Item
has a serious illness or serious sequelae thereof, including liver or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological (including epilepsy), infectious, neoplastic, or metabolic disturbance (if there is a history of such disease but the condition has been stable for at least one year and is judged by the investigator not to render inclusion unsafe and not to interfere with the patient's participation in the study, the patient may be included.)
boolean
C0221423 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0221423 (UMLS CUI [2,1])
C0243088 (UMLS CUI [2,2])
C0205404 (UMLS CUI [2,3])
C1306571 (UMLS CUI [3])
C1565489 (UMLS CUI [4])
C0007222 (UMLS CUI [5])
C0024115 (UMLS CUI [6])
C0017178 (UMLS CUI [7])
C0014130 (UMLS CUI [8])
C0027765 (UMLS CUI [9])
C0014544 (UMLS CUI [10])
C0009450 (UMLS CUI [11])
C1882062 (UMLS CUI [12])
C0025517 (UMLS CUI [13])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial